In oncology, progression-free survival time, which is defined as the minimum of the times to disease progression or death, often is used to characterize treatment and covariate effects. We are motivated by the desire to estimate the progression time distribution on the basis of data from 780 paediatric patients with choroid plexus tumours, which are a rare brain cancer where disease progression always precedes death. In retrospective data on 674 patients, the times to death or censoring were recorded but progression times were missing. In a prospective study of 106 patients, both times were recorded but there were only 20 non-censored progression times and 10 non-censored survival times. Consequently, estimating the progression time distribution is complicated by the problems that, for most of the patients, either the survival time is known but the progression time is not known, or the survival time is right censored and it is not known whether the patient's disease progressed before censoring. For data with these missingness structures, we formulate a family of Bayesian parametric likelihoods and present methods for estimating the progression time distribution. The underlying idea is that estimating the association between the time to progression and subsequent survival time from patients having complete data provides a basis for utilizing covariates and partial event time data of other patients to infer their missing progression times. We illustrate the methodology by analysing the brain tumour data, and we also present a simulation study.
Introduction
A clinical outcome that is commonly used to characterize the effects of treatments for cancers and other potentially fatal diseases is the progression-free survival (PFS) time, which is defined as the time from the start of treatment to disease progression (worsening) or death, whichever occurs first. Denote the time to death without progression by T 0 , the time to progression by T 1 and the time from progression to death by T 2 . Thus, aside from censoring, either T 0 or .T 1 , T 2 / is observed for each subject, the PFS time is min{T 0 , T 1 }, and overall survival (OS) time is T = min{T 0 , T 1 + T 2 }: For diseases where progression always precedes death, i.e. T 0 is never observed, T 1 and the PFS time are identical and the OS time is T = T 1 + T 2 . In this case, a wide variety of time-to-event regression models and methods may be applied (Therneau and Grambsch, 2000; Ibrahim et al., 2001; Klein and Moeschberger, 2003) for estimating the distributions of T 1 , T 2 and T as functions of a vector Z = .Z 1 , . . . , Z q / of covariates and treatment variables. In this setting, the problem of estimating the distribution of [T 1 |Z] becomes more difficult if, for some subjects, either T is known but T 1 is not known, or T is right censored and it is not known whether the subject's disease progressed before the censoring time. For data that have either of these missingness structures, we formulate a family of parametric likelihood functions and present methods for estimating the progression time distribution. Intuitively, the idea underlying our approach is that estimating the joint distribution of T 1 and T 2 from subjects having complete data including Z provides a basis for utilizing the partial information in the value of T or its censoring time and Z to infer T 1 when data for T 1 are missing in either of the two ways that were described above.
Our research is motivated by a data set that arose from 780 patients with choroid plexus tumours. These are rare brain tumours that typically occur in young children, subclassified histologically by the World Health Organization as the comparatively more benign choroid plexus papilloma, the intermediate atypical choroid plexus papilloma and the most malignant histology choroid plexus carcinoma (CPC). Each patient received surgery, and possibly some combination of radiation and chemotherapy. Surgery achieving gross total resection (GTR) is traditionally believed to be of high prognostic relevance (Wolff et al., 2002) , whereas the roles of radiation and chemotherapy are less well understood (Wolff et al., 1999) . As these tumours are rare, sufficient prospectively collected data to evaluate PFS and OS reliably and thus to establish benchmarks for treatment have not been available. Therefore, the data came from two sources: literature and a prospective clinical study. A systematic literature search was undertaken to collect and codify all published case reports (Wolff et al., 1999 (Wolff et al., , 2002 , resulting in 674 cases. These case reports typically included the OS time but rarely included the PFS time. In contrast, the data resulting from a prospective study of 106 patients (Wrede et al., 2009 ) did include both PFS and OS times. Consequently, among the total of 780 patients, 674 patients had observed or censored values of T without observing the value of T 1 , whereas 106 patients had observed or censored values of T 1 and T 2 .
Considerable research has been conducted for survival data analysis with missing failure indicators. Dinse (1982) proposed a Kaplan-Meier-type estimator using the non-parametric maximum likelihood method and the EM algorithm. Lo (1991) developed two alternative estimators that are strongly consistent and converge to Gaussian processes. In the context of a competing risks model, Goetghebeur and Ryan (1990) derived a modified log-rank test to compare survival in two groups when failure types are missing for some individuals and later extended that approach to proportional hazards regression models (Cox, 1972; Goetghebeur and Ryan, 1995) . Lu and Tsiatis (2001) and Tsiatis et al. (2002) took a different approach and proposed the use of multiple imputation to address the problem of missing information on the cause of failure. More recently, Gijbels et al. (2007) introduced a class of estimating functions for the regression parameter of the Cox proportional hazards model to allow unknown failure statuses on some study subjects. Although related, the problem that we consider here is rather different from the situations that were considered in the literature noted above. First, in our case the missing information is more severe in the sense that, in addition to missing failure indicators, T 1 is completely missing for some patients, with only T observed. Moreover, we consider a bivariate survival function for .T 1 , T 2 /, whereas the above literature focused on the univariate case.
Our data structure also shares some similarity to semicompeting risks data (Fine et al., 2001 ) in the sense that disease progression can be viewed as an intermediate non-terminating event, with death a terminating event. However, there are some important differences. For the choroid plexus tumour data, death must be preceded by disease progression owing to the nature of the disease; in other words, the terminating event cannot censor the non-terminating event. This is different from semicompeting risks data, which are characterized by the feature that the terminating event can censor the non-terminating event. In addition, in semicompeting risks data, for subjects who experienced the terminating event it typically is known whether or not they experienced the intermediate non-terminating event. However, in our data set, the status of disease progression may be missing.
Section 2 describes a general probability model that accounts for missing information of the forms that were described above and presents a family of accelerated failure time (AFT) models for the marginals of T 1 and T 2 . Numerical methods for model fitting and estimation are presented in Section 3. In Section 4, the methods are illustrated by an analysis of the data set that motivated this paper. In Section 5, we assess the goodness of fit of the proposed model by using a Bayesian χ 2 -test, and we present sensitivity analyses to assess effects of betweenstudy heterogeneity, the copula that is assumed to obtain a bivariate distribution for .T 1 , T 2 / and the values of prior parameters characterizing association between T 1 and T 2 as well as location and scale in the marginal distributions. We evaluate the performance of the proposed method by using a simulation study in Section 6, and we close with a brief discussion in Section 7.
Probability model

General form of the likelihood
Let θ denote the vector of model parameters. For j = 1, 2, denote the marginal probability density function, cumulative density function and survivor function of [T j |Z] by f j .t|Z, θ/, F j .t|Z, θ/ and S j .t|Z, θ/ = 1 − F j .t|Z, θ/: Denote the administrative right censoring time by C, with observed times T o 1 = min{T 1 , C}, T o 2 = min{T 2 , C − T 1 } and T o = min{T , C}: In addition to right censoring, we account for the possibilities that either it is known that progression occurred but the value of T 1 is not known, or T o < T and it is not known at T o whether progression has occurred. To keep track of all possible cases, we define the following categorical indicator variable:
i fT 1 andT 2 both are observed, 2 i fT 1 is observed and T 2 is censored, 3 i fT 1 is censored, 4 i fT is observed and T 1 is unknown, 5 i fT is censored and it is not known whether progression occurred:
We define the corresponding indicators δ j = I.Δ = j/ for j = 1, . . . , 5. For brevity, we denote
T o / and δ = .δ 1 , . . . , δ 5 /: Each subject's likelihood contribution takes one of five possible forms. Denote the joint probability density function of [T 1 , T 2 |Z] by f 1,2 .t 1 , t 2 |Z, θ/: If T 1 and T 2 are both observed, then the likelihood is
. 2/ If T 1 is censored, then it is known that T 1 > T o 1 but nothing is known about T 2 , and it follows that the likelihood is
The above three cases are those seen most commonly in practice. The next two cases may be considered non-standard in that they are seen less often. If the time of death T o = T = T 1 + T 2 is observed but T 1 is not known, possibly because T 1 was not recorded, then the likelihood is
This is the convolution of T 1 and T 2 evaluated at the observed survival time T = T o . The fifth possibility is that the subject is known to be alive but it is not known whether disease progression has occurred, formally, T >T o but T 1 is not known. In this case, since
the likelihood contribution is
To obtain a joint distribution f 1,2 for given marginals, we assume the Clayton (1978) copula,
. 6/ Under this model, the correlation parameter φ is related to Kendall's τ by the equation τ = 1=.2φ + 1/. Either a large positive value of τ or a small value of φ corresponds to a large positive correlation between T 1 and T 2 , with τ = 1 if φ = 0. Independence of T 1 and T 2 corresponds to τ = 0, which is obtained if φ → ∞. Thus, the Clayton copula assumes that the correlation between the time to progression T 1 and the time from progression to death T 2 is non-negative. This assumption is quite reasonable here because choroid plexus tumour patients with longer time to progression T 1 are more likely to have a longer subsequent survival time T 2 , which also is the case with many other types of cancer. Below, we shall assess the effects of assuming the particular form (6) by repeating the model fit using a bivariate copula (Hougaard, 1986) that has a very different form. Shih and Louis (1995) discussed inferences on the association parameter in copula models for bivariate survival data.
To simplify the notation, we temporarily suppress the arguments Z and θ in f 1 , f 2 , S 1 and S 2 , and we denote ζ = .φ + 1/=φ. Under the Clayton copula, the general forms of the likelihood given by equations (1), (2), (4) and (5) take the following forms:
Specific distributional forms for the marginals
To incorporate covariates, we assume that each marginal belongs to the family of AFT models, characterized by the hazard function
where the covariate and treatment effects are the parameters β = .β 1 , . . . , β q / in the linear term
Under the AFT model, the cumulative hazard function is
and the survivor function is S.t/ = exp{−Λ.t/}: The AFT family is quite broad, with a particular distribution obtained by assuming a specific form for the baseline hazard function λ 0 .
To obtain a good fit to the brain tumour data, we shall consider four possible distributional forms for each of the baseline hazards corresponding to T 1 and T 2 . These are the exponential, Weibull, log-normal and log-logistic distributions, for a total of 16 possible models. To choose a single best model for analysis of the data at hand, we shall assess the goodness of fit by using the Bayesian information criterion (Schwarz, 1978) . Index the event times by j = 1, 2 and denote the linear components η j = β j,1 Z 1 + . . . + β j,q Z q : Since the exponential distribution is characterized by constant baseline hazard function λ 0 .t/ ≡ γ for γ > 0, the covariate-adjusted exponential AFT hazard of T j is λ j,exp .t|Z, β j , γ j / = exp.η j /γ j :
. 7/
The Weibull model has baseline hazard λ 0 .t/ = γαt α−1 , for γ, α > 0, so the covariate-adjusted Weibull AFT hazard of T j is
Denoting the probability density function and survivor function of the log-normal distribution having mean exp.μ + γ=2/ and variance {exp.γ/ − 1} exp.2μ + γ/ for real-valued μ and γ > 0 by f LN .t; μ, γ/ and S LN .t; μ, γ/, since the baseline log-normal hazard function is λ 0 .t; μ, γ/ = f LN .t; μ, γ/=S LN .t; μ, γ/, it follows that the covariate-adjusted log-normal AFT hazard function of T j is
Finally, the log-logistic baseline hazard function is λ 0 .t/ = γαt α−1 =.1 + γt α−1 /, so the covariate-adjusted log-logistic AFT hazard function of T j is
. 10/
Numerical methods and estimation
Although we adopt a parametric approach, the likelihood does not have a simple closed form because the non-standard cases given by L 4 .T o , δ|Z, θ/ and L 5 .T o , δ|Z, θ/ involve integrals that must be evaluated numerically. This makes it challenging to evaluate the first and second derivatives of the likelihood, which is often needed for maximum likelihood methods such as Fisher scoring. To avoid this difficulty, we fit the model by using the Gibbs sampler by generating unknown parameters sequentially from their full conditional posterior distributions. This approach does not require evaluating the derivatives of the likelihood. Let p.θ/ denote the prior distribution of θ. We assume that the components of θ are mutually independent a priori. Given data from n subjects, the posterior distribution of θ is
Following Ibrahim et al. (2001) , chapter 2, we assume independent improper priors on the elements of β 1 and β 2 , which we denote by β jr ∝ 1, for j = 1, 2 and r = 1, . . . , q: Thus, the posteriors are determined mainly by the observed data. For the exponential distributions, we assume gamma priors for the scale parameter, γ j ∼ Ga.a 1 , b 1 /, where Ga.a, b/ denotes a gamma distribution with mean a=b and variance a=b 2 : For the Weibull baseline hazards, we assume α j ∼ Ga.a 2 , b 2 / and γ j ∼ Ga.a 3 , b 3 /. For the log-normal baseline hazards, we assume a uniform improper prior for the location parameter and a gamma prior for the scale parameter, μ j ∝ 1 and γ j ∼ Ga.a 4 , b 4 /. For the log-logistic baseline hazard, we assume that α j ∼ Ga.a 5 , b 5 / and γ j ∼ Ga.a 6 , b 6 /. We set a j = b j = 0:01 for each j = 1, . . . , 6, which is a gamma distribution with mean 1 and variance 100, to reflect vague prior information on the unknown positive parameters. Under these priors, because the posterior full conditional distributions of the parameters do not have closed forms, we computed the posteriors by using the adaptive rejection Metropolis sampling method of Gilks et al. (1995) . We evaluated the integrals appearing in the likelihoods L 4 and L 5 numerically by using adaptive Gaussian-Kronrod quadrature (Piessens et al., 1983) . In the Markov chain Monte Carlo algorithm we used 500 iterations to burn in the chains and 5000 iterations to compute the posterior samples. For initial values in the Markov chain Monte Carlo algorithm, we used the maximum likelihood estimates of the parameters of the marginals for T 1 and T 2 based on the smaller data set consisting of 106 patients having complete data.
Analysis of the brain tumour data
In this section, we apply the proposed methodology to the brain tumour data. Although T 1 and T 2 or their censoring times were recorded for 106 out of a total of 780 patients, the censoring rate was very high. Among the smaller sample of 106, only 20 disease progression times T 1 were observed, with 81.1% of the T 1 -values censored. Because T 2 is observable only if T 1 is observed, the information regarding T 2 was even more limited. Among the 20 patients with observed T 1 -values, 10 values of T 2 were observed and 10 were censored. Among the 674 patients with missing values of both T 1 and T 2 , the sum T = T 1 + T 2 was observed for 182 patients and the remaining 492 values of T were censored. Thus, although the total sample size was 780, most of the information consisted of values of T 1 + T 2 , with uncensored .T 1 , T 2 / pairs fully observed in only 10 patients. Consequently, our analyses relied heavily on covariate information, as well as the strong assumption that the two data sets were exchangeable. Below, we shall conduct a sensitivity analysis to assess potential between-study effects.
As noted above, we conducted a preliminary model selection and goodness-of-fit analysis to choose one best parametric model by considering four distributional forms for each marginal, including the exponential, Weibull, log-normal and log-logistic models, given by expressions (7)-(10). For each regression model, the linear terms η 1 and η 2 each include four covariates: age (z 1 ), histology (z 2 = 1 for CPC and z 2 = 0 for atypical choroid plexus papilloma or choroid plexus Table 1 shows the Bayesian information criterion values of the 16 models that were considered. On the basis of this analysis, the model that fits the data best has log-logistic baseline hazard for T 1 and Weibull baseline hazard for T 2 : The posterior parameter estimates under this model are given in Table 2 , and Fig. 1 shows the posterior distributions of the covariate parameters.
In the model, for each outcome j = 1, 2, a positive value of the coefficient β j,k corresponds to a larger hazard and thus on average a smaller value of T j : Table 2 shows that, for T 1 , a CPC histology and presence of metastatic disease are prognostic factors for faster progression, whereas older age and achieving a GTR with surgery are both desirable. This is shown graphically by Fig. 1 . The posteriors of β 11 for age and β 13 for GTR are mostly below 0, and the posteriors of β 12 for CPC and β 14 for metastases are mostly above 0. For the covariate parameter estimates of the distribution of T 1 in Table 2 , the magnitude of the negative posterior mean effect of age is larger when using all available data compared with the complete-case analysis, with Pr(β 11 > 0|data) decreasing from 0.40 based on the fit using only the 106 complete cases to 0.02 based on the fit using all 780 cases. Similarly, going from the complete cases to the full data set, the magnitude of the positive posterior mean effect of metastases is larger, with (β 14 > 0|data) increasing from 0.65 to 0.93. The posterior standard deviations of all four covariate parameters were larger in the fit using all available data, probably because of the extra variability that is introduced by the heterogeneous observations collected from the literature. In contrast, there were no substantive differences between the fits for any of the covariate parameters of T 2 by using the complete cases versus using all available cases. This result might be expected on the basis of the consideration that the information regarding T 2 in the combined data set essentially came from the smaller data set, since T 2 was never observed directly in the larger data set.
Model diagnostics and sensitivity analyses
We assessed the goodness of fit of the proposed model by using the Bayesian χ 2 -test for censored data that was proposed by Cao et al. (2010) . The Bayesian χ 2 -test is based on squared differences between observed and expected frequencies for a given partition of the sample space and assesses the adequacy of the posited model by graphically comparing the posterior distribution of the squared difference with its null χ 2 -distribution. Specifically, to construct the Bayesian χ 2 -test statistic, we first defined a uniform residual r for each of the observed failure times, T o 1 and T o 2 , as follows. Given T o s and C,
whereθ is a posterior draw of θ. For patients with observed failure times, since their censoring time C was not unobserved it was sampled from its posterior distribution according to the procedure that is described in Cao et al. (2010) . It follows that the residuals are independent and follow a uniform distribution when the model assumed is correctly specified. We partitioned the unit interval into K = 3 equiprobable subintervals. Letting O k denote the number of r-values in the kth cell, and m the total number of observed failure times, the χ 2 -test statistic is given by
. 12/ If the model assumed is correctly specified, S approximately follows a χ 2 -distribution with 2 degrees of freedom, χ 2 2 . Fig. 2 shows the histogram estimates of the posterior distribution of S, which was very close to its null distribution χ 2 2 , suggesting that the model provides an adequate fit to the data.
Although the model diagnostic does not indicate any significant lack of fit, given the high rate of censoring, the power of the diagnostic is limited. Therefore, it is also useful to examine the sensitivity of our analyses to the model assumptions. An important assumption underlying our analyses is that the 674 observations from the literature and the 106 from the prospective study are exchangeable. This assumption is quite reasonable because clinical practice in treating choroid plexus tumours has not changed substantively over the time period encompassing the two data sets. Still, it is important to investigate potential effects of between-study heterogeneity. Although one may attempt to account for possible between-study heterogeneity by specifying distinct regression parameters for the prospective study and the literature review data in each of the marginal regression models of T 1 and T 2 , unfortunately such a model is not identifiable. This is because, since only T 1 + T 2 is observed in the literature review data set, the marginal , χ 2 -distribution with 2 degrees of freedom for reference distributions of T 1 and T 2 are not identifiable for the literature review data. Intuitively, adding an arbitrary value Δ to T 1 and then subtracting Δ from T 2 does not change the value of T 1 + T 2 . Consequently, parameters that characterize the between-study effects are not identifiable.
To address this issue, we conducted a sensitivity analysis to investigate how the inferences are affected when the homogeneity assumption is violated. Let λ jk , j, k = 1, 2, denote the hazard of T j for the literature data set (k = 1) and the prospective study (k = 2). Our sensitivity analysis is based on the following Bayesian hierarchical model for the marginal distributions of T 1 and T 2 . Denoting η jk = β j1k Z 1 + . . . + β jqk Z q , the model for the hazard of T j in data set k for a patient with covariates Z is λ jk .t|Z, β/ = exp.η jk /λ 0 {t exp.η jk /}, β jrk ∼ N.β jr ,σ 2 jr /, r = 1, . . . , q, β jr ∝ 1 whereσ 2 jr is a known parameter that shrinks the literature data set parameter β jr1 and the prospective study parameter β jr2 towards the common hyperparameterβ jr , i.e.σ 2 jr characterizes the heterogeneity between the literature data set and the prospective study. A large value of σ 2 jr corresponds to high between-study heterogeneity, whereas ifσ 2 jr → 0 the covariate effects are homogeneous between the two data sets, i.e. β jr1 = β jr2 for all j and r. To accommodate different scales of {β jrk } and to facilitate the sensitivity analysis, we setσ jr = τβ jr whereβ jr is the estimate of β jr under the homogeneity assumption (see Table 2 ) and τ can be interpreted as the coefficient of variation, i.e. the ratio of the standard error to the mean. We fitted the above Bayesian hierarchical model, with the Clayton copula (6), using a range of values of τ . Fig. 3 shows how the posterior mean estimates of the β jr s vary with τ , the between-study heterogeneity. Although some covariate effects (e.g. β 12 and β 22 for histology) appear relatively more sensitive to τ than others (e.g. β 11 and β 21 for age), overall the covariate effects are not particularly sensitive to between-study heterogeneity.
To investigate the sensitivity of our results to the assumed Clayton copula, we also fitted the data by using the Gumbel-Hougaard copula (Hougaard, 1986) ,
We chose this copula because its functional form is very different from that of the Clayton copula. Under this model, the association parameter ϕ is related to Kendall's τ via the formula τ = 1 − 1=ϕ. A summary of the fitted model under the Gumbel-Hougaard copula model is given in Table 3 . With the exceptions of γ 2 and β 24 , the posterior parameter estimates are very similar to those obtained under the Clayton copula. This indicates that, for this data set, inferences are not sensitive to the choice of copula that is used to obtain a bivariate survival model for the given marginals. Although the estimate of the association parameter ϕ under the Gumbel-Hougaard copula model is numerically similar to that of the association parameter Fig. 3 . Sensitivity analysis of covariate effects with respect to the study heterogeneity †To assess sensitivity to the assumed variance 100 for the gamma priors (a j = b j = 0:01), the model was refitted by using gamma priors for the shape and scale parameters assuming variances of 10 (a j = b j = 0:1) or 10000 (a j = b j = 0:0001). To assess sensitivity to the assumed Clayton copula, the model was refitted by using a Gumbel-Hougaard copula. To facilitate comparisons, the estimates under the Clayton copula with gamma priors from Table 2 are repeated.
φ under the Clayton copula model, the estimated associations between T 1 and T 2 are quite different under the two models. This is because the association parameters of the two models have different meanings, with Kendall's τ -value 0.16 under the Clayton copula and 0.49 under the Gumbel-Hougaard copula. Such a difference is not completely unexpected, however, since data typically contain much less information about association parameters compared with covariate effect parameters. In the present setting, information about the association parameter comes mainly from the small data set of 106 patients for whom both T 1 and T 2 were observed. Moreover, given the small number of events in this data set, it is difficult to estimate the association parameter reliably, as demonstrated by the large posterior standard deviations of these parameters.
We conducted another sensitivity analysis by refitting the model, assuming the Clayton copula, for each of a series of values of the prior mean of φ. This strategy was advocated by Rotnitzky et al. (1998 Rotnitzky et al. ( , 2001 . We assumed informative gamma distributions for φ with a small variance of 0.004 and the mean fixed, successively, at the values 0.1, 0.2, 0.5, 1, 2, 4, 8 and 16. Fig. 4 shows the resulting posterior mean model parameter values as functions of the prior mean of φ. Fig. 4 shows that all parameters, except γ 2 , are robust to the prior mean of φ. The sensitivity of γ 2 to the prior mean of φ is consistent with the observation that the value ofγ 2 is different under the Clayton and Gumbel-Hougaard copulas, since these two models yielded different estimates of the association between T 1 and T 2 in terms of Kendall's τ .
We also assessed the sensitivity of our results to prior specifications of the location and scale parameters under the log-logistic model and to the shape and scale parameters under the Weibull model. To do this, we considered two more priors for these positive parameters: a relatively informative prior Ga.0:1, 0:1/, which has variance 10, and a very diffusive prior Ga.0:0001, 0:0001/, which has variance 10000. The results under these priors, which are given in Table 3 , are quite similar to those displayed in Table 2 . This suggests that our results are not sensitive to the gamma prior's variances in this range, when the prior mean is set equal to 1. 
Simulation study
We conducted a simulation study to evaluate the performance of the proposed method when the data are heavily censored, as in the case of the motivating example. We generated bivariate time-to-event data .T 1 , T 2 / based on the Clayton copula with T 1 and T 2 marginally following the log-logistic and Weibull AFT models respectively. In the AFT models, we included two covariates: a continuous covariate Z 1 generated from a standard normal distribution and a binary covariate Z 2 generated from a Bernoulli distribution with probability parameter 0.5. In the log-logistic AFT model .10/ for T 1 , we set α 1 = 0:45, λ 1 = 0:03 and the two regression coefficients β 1 = β 2 = 0:5. In the Weibull AFT model .8/ for T 2 , we set α 2 = 0:3, λ 2 = 0:12 and the two regression coefficients β 3 = 0:5 and β 4 = 0:25. We set the copula association parameter φ = 1, corresponding to moderate correlation between T 1 and T 2 with Kendall's τ equal to 1 3 . We assumed a total of 206 patients, with 106 patients having observed or censored values of T 1 and T 2 and the remaining 100 patients having missing progression statuses. We chose a uniform censoring distribution with the percentage of censoring in the simulated data matching that seen in the brain tumour data, i.e., in the simulated data, on average about 20 patients had T 1 observed (i.e. 81.1% of the T 1 -values were censored), 10 patients had T 2 observed (i.e. 90.6% of the T 2 -values were censored) and 28 patients had T = T 1 + T 2 observed (i.e. 72.0% of the T -values were censored). We simulated 1000 data sets. Table 4 summarizes the simulation results, including the empirical bias, standard error and coverage probability of the 95% credible interval. The simulations show that the estimates of all parameters had small biases, with the coverage of all 95% credible intervals, except for that of φ, close to the nominal value. The 98.5% mean coverage of the posterior credible interval for the association parameter is not surprising, given the general difficulty of estimating such parameters reliably, as well as the structure and high level of missingness that are imposed in the simulation study. These simulation results suggest that the methodology proposed performs well with heavily censored data of the form that is considered here.
Discussion
We have proposed a Bayesian model-based method to estimate PFS when the progression status of some subjects is unknown. Our approach models the marginal distributions of the time to progression and the time from progression to death separately by using AFT models and then links these marginals to obtain a joint distribution by using a copula. Under the Bayesian paradigm, our method incorporates all available information, including both completely observed and partially observed time-to-event data, to make inferences about PFS time. Our sensitivity analyses indicated that the approach proposed is robust to the choice of both the copula model and the prior specification in settings with this type of missing value structure, even when there are high levels of censoring and missingness.
